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Abstract Ratios of urinary 8-hydroxy-2'-deoxyguanosine to 
urinary creatinine (8-OHdG/creatinine) have been considered as 
a good biological indicator of DNA oxidation. Urinary 8-OHdG/ 
creatinine levels of lung cancer patients were evaluated by 
enzyme-linked iramunosorbent assay using a monoclonal anti-
body N45.1 during radiotherapy and chemotherapy. An increase 
in urinary 8-OHdG/creatinine was found in non-small-cell 
carcinoma (non-SCC) patients during the course of radiotherapy. 
SCC patients showed higher levels of urinary 8-OHdG/creatinine 
than the controls. Furthermore, SCC patients with complete or 
partial response to the chemotherapy showed a significant 
decrease in urinary 8-OHdG/creatinine while patients with no 
change or progressive disease showed an increase. 
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1. Introduction 
Radiotherapy and chemotherapy are the primary treat-
ments for non-operable lung cancer [1]. Free radical forma-
tion is the key mechanism responsible for producing cytotox-
icity in the irradiated cells. Reactive oxygen species generated 
by ionizing radiation react with guanine bases in DNA to 
form 8-hydroxyguanine (also as 8-oxo-guanine) [2-6], which 
has been proposed as a key biomarker of oxidative DNA 
damage. It is established that either hydroxyl radical, singlet 
oxygen or photodynamic action is responsible for the forma-
tion of 8-OHdG (reviewed in [7]). The oxidized DNA is con-
tinuously repaired, and the excised deoxyribonucleosides are 
excreted in the urine [8-11]. Anthracyclines such as doxorubi-
cin, which are used in combination chemotherapy against 
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small-cell carcinoma of lung [1], exert their cytotoxicity also 
via reactive oxygen species [12]. 
Recently, the concept of 'persistent oxidative stress in can-
cer' has been hypothesized to partly explain the characteristics 
of tumor biology such as activated transcription factors and 
proto-oncogenes, genomic instability, chemotherapy-resist-
ance, invasion and metastasis [13]. Indeed, increasing evidence 
suggests that malignant cells produce a large amount of hy-
drogen peroxide [14] and have high levels of oxidized DNA 
lesions (reviewed in [13]). 
Previous animal and in vitro studies have shown increased 
levels of 8-OHdG in DNA after irradiation [4,5]. There are, 
however, few clinical studies on this issue. A recent study 
reported an increase in 8-OHdG content in lymphocytes 
DNA of cancer patients during exposure to therapeutic doses 
of ionizing radiation [15]. The levels of urinary 8-OHdG has 
been indicated to be affected by smoking [16] and metabolic 
rate [8]. Tagesson et al. recently reported that high levels of 
urinary 8-OHdG were found in patients subjected to whole 
body irradiation for bone marrow transplantation of leukemia 
and lymphoma patients by the use of automated coupled-col-
umn high performance liquid chromatography (HPLC) [17]. 
Recently, we have developed a monoclonal antibody specif-
ic for 8-OHdG (N45.1), and constructed an enzyme-linked 
immunosorbent assay (ELISA) system for 8-OHdG determi-
nation [18,19]. An easier measurement of urinary 8-OHdG is 
possible by this method than HPLC-based methods. In the 
present study, we for the first time evaluated the changes in 
urinary 8-OHdG excretion during clinical course of radiother-
apy and anthracycline-based chemotherapy for lung cancer 
patients. In addition, we compared urinary 8-OHdG levels 
between 37 lung cancer patients and 52 controls which were 
matched for age, sex and smoking habit. 
2. Materials and methods 
2.1. Patients and controls 
The study was conducted in two Finnish Central Hospitals within 
the same county. 37 cancer patients and 52 controls entered the study. 
Patients were previously untreated persons having histologically veri-
fied lung cancer. None of the patients had received any high-dose 
vitamin supplementation during the 3 months prior to the study. 
The controls were smokers or ex-smokers with no evidence of cancer, 
living in the same county. The mean age was 65.9 (range 43-82) for 
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the patients and 60.3 (range 45-87) for the controls. The lifetime 
cigarette consumption was expressed as pack-years (i.e. packs smoked 
per day X years smoked). The Ethical Committees of both hospitals 
approved the study protocol and an informed consent form was given 
by all the participants of the study. 
The study consisted of three groups: (1) 16 patients (10 squamous 
cell carcinoma, 2 adenocarcinoma, 1 small-cell carcinoma, 1 anaplas-
tic carcinoma and 2 histologically unclassified carcinoma), receiving 
complete cure-aimed radiotherapy, provided urine samples before the 
therapy, after the total cumulative doses of 2, 10 and 30 Gy, and two 
months after the last dose of radiotherapy; urine was collected from 
0 a.m. to 6 a.m. the following day after each cumulative dose. Most of 
the patients were hospitalized throughout the course of radiotherapy 
and received standard hospital diet; (2) 12 patients having small-cell 
carcinoma of lung (clinical data of the patients are published in Table 
1 of reference [12]) received a standard dose of vincristine (1.5 mg/m2, 
maximal dose each time 2.0 mg), doxorubicin (adriamycin; 50 mg/m2) 
and cyclophosphamide (750 mg/m2) iv on day 1. The first urine sam-
ples were collected before the chemotherapy on day 1 from 0 a.m. to 
6 a.m., and the second one before the chemotherapy on day 22 from 
0 a.m. to 6 a.m. when the patients came to receive the second course 
of treatment. The patients were hospitalized for two days before giv-
ing urine samples; (3) a cross-sectional study was done including the 
preceding two groups of patients and 9 new untreated lung cancer 
patients (6 squamous cell carcinoma, 2 adenocarcinoma and 1 histo-
logically unclassified carcinoma) with 52 matched control persons. 
2.2. Evaluation of the clinical response to the therapy 
Response to the therapy was evaluated by the attending oncologist 
according to the criteria of World Health Organization [20]. The 
patients were divided into two groups according to their response as 
follows: complete or partial response group, and no change or pro-
gressive disease group. Complete response (CR) was defined as the 
disappearance of all known disease determined by two observations 
not less than two weeks apart; partial response (PR) as a 50% or 
more decrease in the total tumor mass of those lesions measured 
during two observations not less than four weeks apart; no change 
(NC) as cases where a 50% decrease in the total tumor size could not 
be established, but there also had not been a 25% or greater increase 
in the size of one or more measurable lesions; progressive disease 
(PD) as a 25% or greater increase in the size of one or more meas-
urable lesions or the appearance of new lesions. 
2.3. Urine samples 
Urine samples were obtained from each individual at the first morn-
ing voiding after approximately 6 hours' collection (generally 0 h to 6 
h), and stored at —80°C until analyses. 
2.4. Determination of urinary 8-hydroxy-2'-deoxyguanosine by ELISA 
Urine samples were centrifuged at lOOOOXg for 10 min and the 
supernatant after proper dilution was used for the determination 
with a competitive ELISA kit (8-OHdG check, Japan Institute for 
the Control of Aging, Fukuroi, Shizuoka). The determination range 
was 0.64-2000 ng/ml. The specificity of the monoclonal antibody 
N45.1 used in the competitive ELISA kit has been established 
[18,19]. The values for urinary 8-OHdG determined by conventional 
HPLC method and the ELISA method had a fairly good correlation 
(Ochi, H. and Osawa, T., unpublished data). Urinary creatinine was 
determined by a kit (Creatinine-test, Wako, Osaka). Data were shown 
as the urinary [8-OHdG (ng/ml)/creatinine (mg/ml)] ratio. 
2.5. Statistical analysis 
An analysis of variance (ANOVA) with repeated measurements 
was applied to evaluate the following three items: (1) differences in 
8-OHdG/creatinine between each responding group (CR, PR, NC and 
PD) of patients; (2) changes in 8-OHdG/creatinine during the treat-
ment period; and (3) interaction between the group and the time-
course of treatment. In the chemotherapy group, the changes in 
8-OHdG/creatinine were calculated, and the differences between re-
sponders (CR/PR) and non-responders (NC/PD) were tested using an 
unpaired ί-test. In the cross-sectional study, an ANOVA was used to 
compare the overall lung cancer patients with their matched controls. 
Fisher's least significance difference (LSD) method was used in post 
hoc comparisons to test the influence of small-cell carcinoma of lung 
on 8-OHdG/creatinine. 
3. Results 
The creatinine values in each patient of chemotherapy 
group were intensively followed through the course since the 
W H O criteria of side effects was also reported elsewhere [12]. 
There were no significant changes in the values. Irradiation of 
lung cancer does not usually affect renal function since less 
than 1% of the total dose is scattered to the distance where 
kidney is located [21]. Tumor disappearance in non-small-cell 
carcinoma is so slow that tumor lysis syndrome does not 
occur. 
The results of the changes in urinary 8-OHdG/creatinine 
level after chemotherapy of small-cell carcinoma patients are 
shown in Fig. 1. There was no significant difference in the 
amount of 8-OHdG between the two groups (PR/CR versus 
NC/PD) before the chemotherapy. A repeated measure A N -
OVA showed no significant changes over time for all the 
small-cell carcinoma patients combined (data not shown). 
The temporal pat tern for urine 8-OHdG, however, was mark-
edly different between the two response groups (group X time 
interaction, p = 0.007). The patients showing PR/CR to the 
therapy had a mean decrease of 13.6 in urinary 8-OHdG/cre-
atinine while those with N C / P D showed a mean increase of 
10.9. The change in urinary 8-OHdG/creatinine before and 
after the chemotherapy between the two responding groups 
was statistically significant (p = 0.007, unpaired /-test). 
The changes in urinary 8-OHdG/creatinine in the radiother-
apy group are shown in Fig. 2. The patients were divided into 
two groups on the basis of response to the therapy. There was 
an increasing trend (10 and 30 Gy) in the values during the 
course of radiotherapy. Two months after the radiotherapy, 
urinary 8-OHdG/creatinine returned to the baseline levels. A 
repeated measures A N O V A found a significant difference be-
tween the response groups (PR/CR versus N C / P D , p = 0.02) 
and a significant time effect (p = 0.006). The patients showing 
no response to the therapy revealed more pronounced increase 
in urinary 8-OHdG/creatinine at 10 and 30 Gy than the re-
Table 1 
Demographic data and urinary 8-OHdG/creatinine levels of lung cancer patients before treatment and of matched controls 
Lung cancer patients (JV=37) Controls (N=52) 
Gender (male/female) 
Age 
Smoking (pack-years) 
Urinary 8-OHdG/Creatinine (ng/mg) 
overall 
in SCC (JV=14) 
in non-SCC (iV=23) 
82/18 (%) 
66 ±10 
28 ±17 
22.6 ±13.0 
27.2 ±17.4* 
19.8 ±8.6 
90/10 (%) 
60± 11 
31 ±19 
19.4 ±8.5 
*Significantly higher (p < 0.05, Fisher's least significance difference method) compared to the matched controls and to non-SCC patients. SCC, 
small-cell carcinoma (means ± SD). 
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Fig. 1. Urinary 8-OHdG/creatinine (ng/mg) in patients of small-cell carcinoma of lung before and after the chemotherapy. Individual paired 
data and means!SEM are shown. CR, complete remission; PR, partial remission; NC, no change; PD, progressive disease. Refer materials 
and methods section and results section for detail. 
sponding group (group X time interaction, p = 0.08). Three of 
the patients with PD died before the final measurement. 
In the cross-sectional study, there was no significant differ-
ence between the cancer group and their matched controls in 
urinary 8-OHdG/creatinine level (22.6±13 versus 19.4±8.5; 
means ± SD) as shown in Table 1. The group of small-cell 
carcinoma patients (N= 14) had, however, significantly higher 
values than the control group (27.2±17.4 versus 19.4±8.5; 
p < 0.05, Fisher's LSD test) or than the non-small-cell carci-
noma lung cancer patients (19.8 ± 8.6; p < 0.05, Fisher's LSD 
test). Non-small-cell carcinoma lung cancer patients showed 
no significant difference in urinary 8-OHdG/creatinine excre-
tion from the matched controls. 
In the cross-sectional study, the lung cancer patients were 
slightly older than the healthy controls (66 versus 60 years), 
but there were no significant differences between the groups 
with regard to gender or smoking habits. None of these var-
iables correlated with the baseline urinary 8-OHdG/creatinine 
level in the present study. 
4. Discussion 
The major findings in our study are that (1) oxidative DNA 
damage, as expressed by urinary 8-OHdG/creatinine level, in-
creased during the course of radiotherapy in lung cancer pa-
tients with no change/progressive disease response, (2) small-
cell carcinoma patients had higher levels of urinary 8-OHdG/ 
creatinine before therapy than control subjects or non-small-
cell carcinoma lung cancer patients, (3) significant increase in 
urinary 8-OHdG/creatinine was observed after chemotherapy 
in small-cell carcinoma patients with no change/progressive 
disease response whereas significant decrease in urinary 8-
OHdG/creatinine was found in small-cell carcinoma patients 
with complete remission/partial remission response. 
Previous experimental studies have indicated increased lev-
els of 8-OHdG in cells and tissues after irradiation [4,5] and 
this has recently been confirmed in clinical situations as well 
[15,17]. The present report is the first to show an increase in 
urinary 8-OHdG in lung cancer treatment. The maximal uri-
nary excretion of 8-OHdG/creatinine was observed after total 
cumulative doses of 10 and 30 Gy. It is crucial to note that the 
patients showing radiation therapy-resistance showed more 
pronounced increase in their values than did the responding 
ones. These results are likely to be affected by the decrease in 
the tumor mass via radiation-induced necrosis. Our data sug-
gests that tumor necrosis is not the cause of increase in uri-
nary 8-OHdG/creatinine levels. However, this has to be care-
fully elucidated. 
We found no difference in urinary 8-OHdG/creatinine ex-
cretion between the overall lung cancer patients participated 
in the present study and their matched controls. The small-cell 
carcinoma patients, however, had significantly higher levels of 
urinary 8-OHdG/creatinine than the controls. Small-cell car-
cinoma of lung is a highly malignant systemic disease charac-
terized by rapid and wide spread dissemination of the tumor 
cells at the time of diagnosis. We have previously reported a 
decreased plasma peroxyl radical trapping capacity in small-
cell carcinoma patients [22]. Thus, it appears that lung cancer 
of this histologic type is associated with an increased oxidative 
stress that is most likely to be due to the systemic nature of 
the disease. 
Small-cell carcinoma of lung is highly sensitive to chemo-
therapy and most of the patients respond to the initial treat-
ment. In 30^10% of the cases, CR will be obtained. Survival 
beyond 5 years is, however, achieved in only 10-20% of the 
patients with limited disease and 3-5% of the patients with 
extensive disease [1,23]. Seven patients in our study showed 
initial CR or PR to the therapy. The levels of 8-OHdG/crea-
tinine clearly decreased compared to the baseline in these 
patients. We believe that this reduction reflects the decrease 
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Fig. 2. Urinary 8-OHdG/creatinine (ng/mg) in patients of non-small-cell carcinoma of lung before, during and after the radiotherapy (means 
±SEM; PR/CR, 7V = 9; NC/PD, N=l). Refer materials and methods section and results section for detail. 
in the tumor mass and, thus, a relief of oxidative stress as 
well. In contrast, patients with PD or NC response showed 
a significant increase in urinary 8-OHdG/creatinine levels. 
Urinary 8-OHdG has been proposed as a highly sensitive 
index of oxidative stress, but various individual factors such 
as smoking [16,24] have been reported to possibly affect its 
levels. We analyzed the data in consideration of the effect of 
smoking. Diet is unlikely to be a confounding factor here 
because most of the patients were hospitalized during the 
therapy and thus received a standard hospital diet. Further-
more, it was shown in animal experiments that urinary 8-
OHdG levels were not affected by the nucleic acid content 
of the diet though urinary 8-hydroxyguanine levels were af-
fected [8]. 
The ELISA method we have used in the present experiment 
depends on the specificity of monoclonal antibody N45.1 for 
8-OHdG since this antibody recognizes both the modified 
base and deoxyribose structure [19]. The ELISA method is 
superior to HPLC methods in the following aspects: (1) no 
need for any expensive equipment except an ELISA reader; 
(2) reduced analyzing time; (3) low running cost; and (4) 
small urine sample volume required. This method will be use-
ful in a variety of experiments and clinical settings. 
5. Conclusion 
Our original findings warrant further clinical prospective 
studies especially in small-cell carcinoma of lung. It is tempt-
ing to speculate that a follow-up of urinary 8-OHdG/creati-
nine might in the future be a useful tool to evaluate the re-
sponse to therapy and help in selecting the patients who are 
most likely to benefit from the treatments. This potential use 
is quite timely considering the heated discussion in Great 
Britain just now about totally quitting small-cell carcinoma 
treatments due to their poor cost-benefit ratio in public health 
care. 
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